Market Newsdesk

Nyxoah to Participate in the Piper Sandler 37

^th

Annual Healthcare Conference

Mont-Saint-Guibert, Belgium – 27 November, 2025, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the management team will participate in a fireside chat at the Piper Sandler 37^th Annual Healthcare Conference on Thursday, Dec. 4, 2025. The fireside chat is scheduled at 1:30 p.m. (ET) the same day via webcast.

A live audio webcast of the presentation will be available online at the investor relations page of the Company’s website at investors.nyxoah.com.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest.

Following the successful completion of the BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company announced positive outcomes from the DREAM IDE pivotal study and receipt of approval from the FDA for a subset of adult patients with moderate to severe OSA with an AHI of greater than or equal to 15 and less than or equal to 65.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. FDA approved in August 2025 as prescription-only device.

Contact:

Nyxoah

John Landry
Chief Financial Officer
[email protected]

Rémi Renard
Chief Investor Relations & Corporate Communication Officer
[email protected]

Attachment

• ENGLISH_NYXH Piper Conf Advisory PR_2025

TORONTO, Nov. 27, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired Part 2 of a three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation.

Award-winning CTV News journalist and W5 investigative reporter Jon Woodward provides highlights of Part Two of the series in an article entitled, “‘Something was wrong’: Inside a Canadian biotech firm’s fight to prove ‘stock spoofing’”. The series explores the phenomenon of “stock spoofing,” a market manipulation tactic that is illegal in Canada and the United States, and the basis of a USD $700 million lawsuit by Quantum Biopharma against two of Canada’s largest banks, CIBC and RBC.

The second of the three-part W5 investigative series can be viewed today on CTV News at: W5: Quantum BioPharma seeks $700M in stock spoofing lawsuit.

Part 1 can be viewed at: W5: MS research derailed by stock market spoofing: lawsuit.

Quantum BioPharma Chief Executive Officer Zeeshan Saeed commented, “We thank W5 for their important investigation into the illegal, but little known, practice of stock spoofing and some of its harmful effects on retail investors. Our goal has always been to bring Lucid-MS – a potentially game-changing drug that in animal studies has been shown to stop and even reverse the degradation of nerve cells (a hallmark of multiple sclerosis) giving back mobility and control to the body unlike any drug today for the benefit of millions of people around the world who courageously live with this progressive and debilitating disease. By shining a light on our experience with alleged stock market manipulation, we hope to prevent other companies, their shareholders and their beneficiaries, from experiencing what we have been through.”

Quantum BioPharma Co-Executive Chair, Anthony Durkacz added, “The basis of our USD $700 million lawsuit against CIBC and RBC is that we are alleging Canadian exchange trading data clearly show stock spoofing on a massive scale intended to manipulate Quantum BioPharma’s stock price. It is the banks and the brokers that have the responsibility to act as gatekeepers, and to ensure that their clients and their traders are not breaching trading rules and regulations, or engaging in illegal activity such as stock spoofing. We are alleging that at least 16 million illegal and fictitious orders came from Canadian bank platforms.”

For more information visit: www.quantumbiopharma.com

About Quantum BioPharma Ltd.

Quantum BioPharma (NASDAQ: QNTM) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (“Lucid”), Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. Quantum BioPharma invented unbuzzd™ and spun out its OTC version to a company, Celly Nutrition Corp. (“Celly Nutrition”), now Unbuzzd Wellness Inc., led by industry veterans. Quantum BioPharma retains ownership of 19.86% as of September 30, 2025 of Unbuzzd Wellness Inc. at www.unbuzzd.com. The agreement with Unbuzzd Wellness Inc. also includes royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million. Once $250 million is reached, the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses. Quantum BioPharma maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property. For more information visit www.quantumbiopharma.com.

Forward-Looking Information

This press release contains certain “forward-looking statements” within the meaning of applicable securities law. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, objectives, assumptions or future events or performance (often, but not always, identified by words or phrases such as “believes”, “hopes”, “alleges”, “pending”, “further”, or variations of such words and phrases or statements that certain actions events or results “may”, “could”, “which”, or “will” and similar expressions) are not statements of historical fact and may be forward-looking statements. Forward-looking information herein includes, but is not limited to, statements regarding: the Company’s ongoing litigation against major financial institutions; the potential outcome or judgment value; expectations regarding whistleblower submissions and related rewards; continued market integrity initiatives; future business performance and possible acquisitions.

In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation: the ability to obtain and validate whistleblower evidence; the timing and outcome of legal proceedings; resolution of ongoing litigation on favourable terms, availability and sufficiency of litigation funding; continued regulatory compliance and market stability for the Company’s operations.

The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company’s management on the date the statements are made, and they involve a number of risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The above lists of forward-looking statements and assumptions are not exhaustive. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated or implied by such forward-looking statements due to a number of factors and risks. These include: the adverse outcome of legal actions; the receipt and credibility of whistleblower disclosures; changes in applicable laws and regulations; the actions of third parties involved in alleged manipulation; evolving market dynamics; the sufficiency of future litigation proceeds to fund the Company’s whistleblower reward; the continued ability to obtain sufficient litigation funding; limited future growth opportunities, and reliance on key personnel.

Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change.

The reader is urged to refer to additional information relating to Quantum BioPharma, including its annual information form, can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the SEC’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects.

Contacts:

Quantum BioPharma Ltd.

Zeeshan Saeed, Founder, CEO and Executive Co-Chairman of the Board
Email: [email protected]  
Telephone: (833) 571-1811

Investor Relations

Investor Relations: [email protected]
General Inquiries: [email protected]

NEW YORK, Nov. 27, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Jefferies Financial Group Inc. (NYSE: JEF) and Point Bonita Capital for potential violations of the federal securities laws after SEC probe is revealed.

If you invested in Jefferies or Point Bonita, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action.

Why are Jefferies and Point Bonita being Investigated?

Jefferies is an investment banking and capital markets firm. Its trade finance arm is named Point Bonita Capital. Jefferies and Point Bonita were two of the closest banking and financing partners of First Brands Group, LLC, an auto parts supplier which collapsed into bankruptcy in September 2025.

On October 8, 2025, Jefferies announced that it and Point Bonita had approximately $715 million in exposure to First Brands’ receivables, which represents roughly 25% of Point Bonita’s trade finance portfolio. On this news, the price of Jefferies stock fell $4.66 per share, or about 8%, from $59.10 per share on October 7, 2025, to $54.44 per share on October 8, 2025. Investors are reportedly currently seeking redemptions from Point Bonita as well.

On November 27, 2025, it was reported that the SEC is seeking information about whether Jefferies gave investors in its Point Bonita fund enough information about their exposure to the auto business, which filed for bankruptcy in September with $12bn in debt. It was also reported that the SEC is also looking into internal controls and potential conflicts within and between different parts of the bank.

BFA is currently investigating whether Jefferies and/or Point Bonita made materially false and misleading statements to investors in connection with this significant exposure to First Brands and the subsequent SEC probe into the company.

Click here for more information:

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

.

What Can You Do?

If you invested in Jefferies or Point Bonita you may have legal options and are encouraged to submit your information to the firm.

All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.

Submit your information by visiting:

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Or contact:
Ross Shikowitz
[email protected]
212.789.3619

Why Bleichmar Fonti & Auld LLP?

BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360 and “SuperLawyers” by Thomson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.

For more information about BFA and its attorneys, please visit https://www.bfalaw.com.

https://www.bfalaw.com/cases/jefferies-financial-group-inc-class-action

Attorney advertising. Past results do not guarantee future outcomes.

SAN FRANCISCO, Nov. 27, 2025 (GLOBE NEWSWIRE) — Investor rights law firm Hagens Berman reminds investors of the January 12, 2026, deadline to move the Court for appointment as lead plaintiff in the securities fraud class action lawsuit filed against Primo Brands Corporation (NYSE: PRMB) and its predecessor, Primo Water Corporation (PRMW).

The lawsuit alleges that the company misled investors by claiming the integration of its merger was “flawless” when, in reality, it was botched, leading to massive customer service failures and a devastating stock drop.

“The core of this lawsuit is that Primo Brands allegedly concealed severe problems during a critical merger, painting a false picture of operational success while the foundation was cracking,” said Reed Kathrein, the Hagens Berman partner leading the investigation. “We urge investors who suffered substantial losses to contact our firm immediately to discuss their rights.”

Key Allegations & Facts for PRMB Investors

• Class Period:   June 17, 2024 – Nov. 6, 2025
• Lead Plaintiff Deadline:   Jan. 12, 2026
• Core Allegations: Misleading statements that the merger integration was “flawless,” concealing severe technology failures and supply disruptions that caused customer loss and led to a CEO replacement.
• Financial Impact: Stock fell approximately 36% following the November 6, 2025, disclosure of operational failures and the need to slash 2025 revenue forecasts.

What Investors Should Know

The lawsuit alleges that Primo Brands’ executives repeatedly assured investors that the merger was tracking well and would accelerate growth. These statements were allegedly false because the integration was suffering from significant, undisclosed technological and service issues.

The truth began to emerge in stages, culminating on November 6, 2025, when the Company announced a major leadership change, replacing its CEO, and admitted they “probably moved too far too fast on some of the various integration work streams.” This final disclosure confirmed the operational failures, leading to the dramatic 36% stock crash as investors realized the true extent of the financial damage.

Hagens Berman is investigating whether the Company violated federal securities laws by making false or misleading statements to inflate its stock price during the Class Period.

Next Steps for Investors:

If you purchased Primo Brands (PRMB) or Primo Water (PRMW) securities during the Class Period and suffered losses, you may be eligible to serve as Lead Plaintiff. The deadline to file your motion for Lead Plaintiff is January 12, 2026.

TO SUBMIT YOUR PRIMO BRANDS (PRMB) STOCK LOSSES NOW OR FOR A CONFIDENTIAL CONSULTATION:

Visit:
www.hbsslaw.com/investor-fraud/prmb

Contact the Firm Now:
[email protected]

                                       844-916-0895

If you’d like more information and answers to frequently asked questions about the Primo case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Primo should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:

Reed Kathrein, 844-916-0895

SAN FRANCISCO, Nov. 27, 2025 (GLOBE NEWSWIRE) — Investor rights law firm Hagens Berman reminds investors of the January 12, 2026, deadline to move the Court for appointment as lead plaintiff in the securities fraud class action lawsuit filed against Stride, Inc. (NYSE: LRN). The lawsuit alleges that Stride, one of the nation’s largest providers of online educational services, misled investors about its operational health and compliance, resulting in a stock crash of over 54% following damaging disclosures.

“The claims against Stride are particularly troubling, alleging that the company inflated enrollment figures by retaining ‘ghost students’ and then compounded the deception with a disastrous platform upgrade that management was aware of,” said Reed Kathrein, the Hagens Berman partner leading the investigation. “We are actively scrutinizing whether executives knew of these undisclosed facts and urge investors who suffered substantial losses to contact Hagens Berman now to discuss their rights.”

Key Facts for LRN Investors:

• Class Period: October 22, 2024 – October 28, 2025, inclusive.
• Lead Plaintiff Deadline: January 12, 2026.
• Case Status: Securities Class Action pending in the U.S. District Court for the Eastern District of Virginia.
• Core Allegations: The complaint alleges Stride made materially false and misleading statements regarding its business by:
  • Inflating Enrollment: Retaining “ghost students” on enrollees who never officially started or were absent for extended periods.
  • Ignoring Compliance: Cutting costs by increasing student-to-teacher ratios far beyond required limits and ignoring mandated special education services.
  • Undisclosed Operational Failures: Concealing major technical issues from an “upgraded platform” that led to “poor customer experience,” high withdrawal rates, and a devastating loss of 10,000 to 15,000 enrollments.

What Happened and Why it Matters:

The lawsuit stems from two distinct disclosures that revealed the Company’s true condition and triggered massive stock drops:

1. September 14, 2025: A public report surfaced detailing a lawsuit by a school district (Gallup-McKinley), alleging fraud and deceptive practices, including the use of “ghost students” to artificially inflate enrollment and profits. Stride’s stock plunged 11% on this news.
2. October 28, 2025: Stride announced its Q1 fiscal 2026 results, revealing a severe operational issue due to a failed platform upgrade. The poor customer experience and system disruption caused significant enrollment losses. Stride’s stock subsequently crashed over 54% in a single day.

Hagens Berman is investigating whether Stride’s management intentionally misled investors about the stability of its enrollment figures and the severity of its operational and compliance failures to artificially inflate its stock price.

Next Steps for Investors:

If you purchased Stride, Inc. securities during the Class Period (October 22, 2024 – October 28, 2025) and suffered substantial losses, you may be eligible to serve as Lead Plaintiff.

The deadline to file your motion for Lead Plaintiff is January 12, 2026.

TO SUBMIT YOUR LOSSES NOW OR FOR A CONFIDENTIAL CONSULTATION:

Visit:
www.hbsslaw.com/investor-fraud/lrn

Contact the Firm Now:
[email protected]

                                        844-916-0895

If you’d like more information and answers to frequently asked questions about the Stride case and our investigation, read more »

Whistleblowers: Persons with non-public information regarding Stride should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw. 

Contact:

Reed Kathrein, 844-916-0895

Doha, November 26, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON”), announced today that Beeline Uzbekistan will once again partner with the GSMA and the Ministry of Digital Technologies of the Republic of Uzbekistan to hold GSMA M360 Eurasia 2026. This next edition of the region’s flagship digital policy and industry forum will take place for the first time in Samarkand on May 20–21, 2026.

M360 Eurasia’s return to Uzbekistan for a second consecutive year reflects the country’s position as a regional digital hub and the momentum of its Digital Uzbekistan 2030 strategy. Bringing the 2026 event to Samarkand—historically a crossroads of Eurasian exchange—underscores the government’s ambition to make Uzbekistan a platform for modern digital cooperation, innovation, and investment across the region.

Sherzod Shermatov, Minister of Digital Technologies, Republic of Uzbekistan said: “We are honored to welcome the mobile ecosystem to Samarkand, a city that has connected cultures, ideas and trade across Eurasia for centuries. Hosting M360 Eurasia here reflects Uzbekistan’s commitment to building a modern digital economy that draws on this legacy of openness and innovation. As we advance our ambitious Digital Uzbekistan 2030 agenda, partnerships with the mobile industry remain essential to accelerating economic growth and strengthening regional cooperation. We look forward to a productive dialogue between policymakers and industry leaders in Samarkand.”

Kaan Terzioglu, Beeline Uzbekistan Chairman and VEON Group CEO said: “Central Asia is fast becoming a focal point of AI-driven digital development in the emerging world. The 2025 edition of M360 Eurasia in Tashkent captured this energy, bringing together leaders from across the wider region. We are proud to again join the GSMA and Uzbekistan’s Ministry of Digital Technologies to bring M360 Eurasia 2026 to Samarkand and showcase the region’s growing potential.”

John Hoffman, CEO, GSMA Ltd., said: “Hosting M360 Eurasia 2026 in Samarkand reflects our continued commitment to supporting digital transformation and cross-regional collaboration across Eurasia. Samarkand’s unique position as a historic and modern gateway between continents makes it an ideal home for this event. We look forward to bringing together global and regional leaders to advance innovation, investment and connectivity.”

M360 Eurasia 2026 is part of the GSMA’s M360 series, a conference platform cultivating regional engagement through topics that are impacting the mobile industry on both a localised and global scale. Senior executives in mobile and adjacent industry verticals come to learn and discuss in detail their challenges and successes as well as network with peers.

For more information: https://www.m360series.com/

About VEON 

VEON is a digital operator that provides converged connectivity and digital services to nearly 150 million connectivity and 140 million digital users. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com.

About Beeline Uzbekistan

Beeline Uzbekistan is a digital operator that serves 7.7 million customers with mobile connectivity and 7.9 million total monthly active users across its digital services and applications. Its digital portfolio includes financial services application BeePul, digital-first brand OQ, the recently launched streaming application Kinom and super-app hambi. Beelab and VEON Adtech are also also headquartered in Uzbekistan, contributing to software and IT technologies ecosystem in the country. Beeline Uzbekistan is wholly owned by VEON, a Nasdaq-listed company.

Forward-Looking Statements Disclaimer

This release contains “forward-looking statements”, within the meaning of the Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. Such forward-looking statements include, but are not limited to, statements relating to VEON’s commercial partnerships and strategic initiatives. There are numerous risks, uncertainties that could cause actual results and performance to differ materially from those expressed by such statements, including risks relating to uncertainty over VEON’s commercial partnerships and strategic initiatives, among others discussed in the section entitled “Risk Factors” in VEON’s 2024 Form 20-F filed with the SEC on April 25, 2025 and other public filings made by VEON with the SEC. The forward-looking statements contained herein speak only as of the date of this release and VEON disclaims any obligation to update them, except as required by law.

Contact Information

VEON
Hande Asik
Chief Communications and Strategy Officer
[email protected]

Attachment

• Beeline Uzbekistan Chairman and VEON Group CEO Kaan Terzioglu on stage at MWC Doha 2025